List of Excipients in Branded Drug BYLVAY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Ipsen Biopharmaceuticals Inc	BYLVAY	odevixibat	15054-3301	CELLULOSE, MICROCRYSTALLINE	2039-06-20
Ipsen Biopharmaceuticals Inc	BYLVAY	odevixibat	15054-3301	HYPROMELLOSE	2039-06-20
Albireo Pharma Inc	BYLVAY	odevixibat	74528-020	CELLULOSE, MICROCRYSTALLINE	2039-06-20

BYLVAY Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

BYLVAY (odevixibat) uses an oral, pediatric-focused formulation strategy built around low-dose capsules and oral pellets. The commercial value of its excipient platform is tied to dose flexibility, administration to infants and young children, compatibility with soft foods or liquids, and long-term treatment adherence. The strongest opportunities are pediatric delivery, taste and palatability improvement, flexible unit-dose packaging, and differentiated formulations that reduce dosing errors.

What is BYLVAY and which formulations are commercially available?

BYLVAY is odevixibat, a small-molecule ileal bile acid transporter inhibitor marketed by Mirum Pharmaceuticals. It is approved in the United States for:

• Cholestatic pruritus due to Alagille syndrome in patients at least 12 months old.
• Cholestatic pruritus due to progressive familial intrahepatic cholestasis in patients at least 5 years old, under the current U.S. labeling framework.
• Other regional indications and age thresholds may differ.

The product is administered orally in microgram-level doses. U.S. dosage forms include capsules and oral pellets. The pellets are commercially important because the target population includes children who cannot reliably swallow capsules.

Attribute	BYLVAY commercial relevance
Active ingredient	Odevixibat
Pharmacologic class	Ileal bile acid transporter inhibitor
Dosage forms	Capsules and oral pellets
Dose scale	Microgram-level, weight-based dosing
Primary users	Pediatric patients with rare cholestatic liver diseases
Administration challenge	Young children, feeding-tube use, soft-food administration
Main commercial owner	Mirum Pharmaceuticals
U.S. regulatory status	FDA-approved prescription drug
Biosimilar relevance	None; BYLVAY is a small molecule
Generic pathway	Abbreviated New Drug Application, subject to patent and exclusivity barriers

The low dose creates different formulation requirements from conventional tablets or capsules. Dose uniformity, powder containment, blend homogeneity, and accurate administration are central development issues.

What excipients are used in BYLVAY?

The BYLVAY label identifies inactive ingredients for the approved dosage forms. The formulation uses conventional pharmaceutical excipients rather than a highly complex delivery technology. The commercial differentiation comes from the combination of low-dose drug loading, pellet presentation, pediatric administration, and dosing instructions.

Public labeling identifies excipient categories including:

• Microcrystalline cellulose.
• Lactose monohydrate.
• Sodium starch glycolate.
• Magnesium stearate.
• Capsule-shell components for the capsule presentation.
• Colorants and other capsule-shell materials, depending on strength and presentation.

The exact excipient profile should be evaluated by dosage form and strength because capsule shells and pellet presentations can have different inactive-ingredient compositions. FDA labeling and the DailyMed product record are the controlling references for product-specific composition.[1,2]

Why the excipient selection matters

Odevixibat is administered at very low quantities. Excipients therefore perform several technical functions:

1. They increase bulk so the drug can be manufactured, filled, sampled, and administered consistently.
2. They support blend uniformity at low active-ingredient loading.
3. They provide disintegration and dispersion after oral administration.
4. They allow the pellets to be mixed with soft food or liquid.
5. They support a dosage form suitable for pediatric use.

Microcrystalline cellulose is commonly used as a diluent and structural carrier. Sodium starch glycolate can support rapid breakup and dispersion. Magnesium stearate improves manufacturing flow and reduces adhesion during compression or filling, although excessive lubrication can affect wetting and dissolution.

Lactose can improve bulk and processability but requires attention to lactose intolerance, milk-protein concerns, and patient-specific dietary restrictions. Product labeling, rather than broad excipient assumptions, determines whether the formulation is suitable for an individual patient.

What is the excipient strategy behind BYLVAY oral pellets?

The oral-pellet strategy addresses a pediatric administration problem rather than simply changing the product's appearance. Pellets can be administered directly into the mouth or mixed with a small quantity of soft food or liquid, depending on the approved instructions.

Pediatric administration advantages

Pellets can provide:

• Reduced dependence on swallowing ability.
• More practical dosing for infants and young children.
• Easier caregiver administration.
• Better compatibility with weight-based dosing.
• Potential use in patients receiving enteral nutrition, subject to product instructions.
• Less need to manipulate a capsule or split a solid dosage form.

The formulation must maintain dose uniformity when the contents of a packet or capsule are dispersed. A critical commercial requirement is that caregivers administer the entire dose. Residual pellets left in food, cups, syringes, or feeding equipment can create underdosing.

Excipient opportunities in pediatric pellets

The principal opportunity is a next-generation pellet platform with improved:

• Taste masking.
• Mouthfeel.
• Dispersion in a wider range of foods.
• Flow through oral syringes or feeding tubes.
• Stability after brief contact with liquids.
• Resistance to pellet segregation.
• Dose recovery from the administration container.
• Compatibility with refrigerated or room-temperature storage.

Taste masking is particularly relevant because odevixibat treatment may be chronic. A product that minimizes bitterness or grittiness could improve adherence without changing the active ingredient.

Potential technologies include polymer coating, lipid coating, ion-exchange resins, microencapsulation, and multiparticulate matrices. These approaches would require careful control of dissolution because odevixibat acts locally in the ileum and the formulation must not substantially alter the intended exposure profile.

What formulations are protected by BYLVAY intellectual property?

BYLVAY’s intellectual-property value is likely distributed across active-compound, composition, formulation, manufacturing, and method-of-use claims. The commercial relevance of each category differs.

IP category	Potential protection	Commercial effect
Active compound	Odevixibat chemical structure and related compounds	Can delay direct generic substitution
Composition	Drug-excipient combinations and dosage forms	May restrict copying of capsules or pellets
Multiparticulates	Pellet size, coating, release, or administration properties	Can protect pediatric delivery
Method of use	Treatment of cholestatic pruritus and associated diseases	May affect carve-out and label strategy
Manufacturing	Low-dose blending, pellet manufacture, filling, or coating	Can increase generic development costs
Packaging	Unit-dose or moisture-protective presentation	Usually weaker than compound or formulation claims
Pediatric administration	Mixing with food or liquid and dose-delivery methods	May support lifecycle protection

Public FDA sources should be used to confirm current Orange Book-listed patents and expiration dates before making a launch or freedom-to-operate decision.[3] Patent families outside the Orange Book can also matter, particularly for formulation, manufacturing, pediatric administration, and international markets.

How strong is the BYLVAY patent estate?

The strongest potential barriers are compound patents and claims that cover the approved product broadly enough to capture a generic odevixibat product. Formulation patents have greater value if they cover a commercially necessary pellet design rather than optional excipient substitutions.

An excipient patent is commercially stronger when it claims a combination that is difficult to replace without affecting:

• Dose uniformity.
• Dissolution.
• Stability.
• Palatability.
• Administration through feeding equipment.
• Product specifications required by regulators.

A patent limited to a particular diluent or lubricant is easier to design around. A patent covering a complete multiparticulate architecture, particle-size distribution, coating system, and administration method is more difficult to avoid.

When does BYLVAY lose exclusivity?

BYLVAY has several forms of exclusivity that must be assessed separately:

1. FDA regulatory exclusivity.
2. Orange Book-listed patent exclusivity.
3. Pediatric exclusivity, if granted.
4. Orphan-drug exclusivity.
5. International data and market exclusivity.
6. Commercial exclusivity created by manufacturing complexity and limited patient volume.

Orphan-drug exclusivity can restrict approval of the same drug for the same indication for seven years in the United States, subject to statutory exceptions. Patent expiry may occur before or after that period. The practical generic-entry date depends on the earliest enforceable barrier, litigation outcome, settlement terms, and the scope of any approved generic label.

The FDA Orange Book remains the primary public source for listed patents and regulatory exclusivity. FDA approval letters, product labeling, and the Orange Book should be reviewed together because no single source captures every commercial barrier.[1,3]

Which companies are challenging BYLVAY with generics?

No biosimilar competition is relevant because odevixibat is a small molecule. Potential challengers would file ANDAs rather than abbreviated applications under the biosimilar pathway.

A generic competitor could pursue one of several strategies:

• A full-label ANDA after all relevant exclusivity expires.
• A Paragraph IV certification alleging that an Orange Book-listed patent is invalid, unenforceable, or not infringed.
• A section viii labeling carve-out for patented methods of use.
• A different excipient composition with the same active ingredient and dosage form.
• A capsule-only product if pellet claims or pediatric administration claims remain protected.

Publicly visible generic competition should be monitored through FDA ANDA approvals, Paragraph IV notices, Hatch-Waxman litigation dockets, and settlement disclosures. The lack of a public challenge does not eliminate future risk because rare-disease markets can attract specialty generic companies after revenue reaches a commercially viable threshold.

What Paragraph IV risks exist for BYLVAY?

A Paragraph IV challenge could target:

• The odevixibat compound.
• The approved capsule formulation.
• The oral-pellet formulation.
• A method-of-use patent covering cholestatic pruritus.
• A formulation or manufacturing patent listed in the Orange Book.

The most credible challenge would likely focus on invalidity or non-infringement of formulation claims, particularly if a generic developer can use alternative excipients while matching the reference product's bioavailability and performance.

A generic applicant may also seek approval for a narrower label. This can reduce method-of-use infringement risk, but it creates regulatory and commercial limits if the carved-out indication is important to prescribing behavior.

For a low-dose pediatric product, bioequivalence may be technically demanding. A challenger must manage:

• Very low active-ingredient concentration.
• Analytical assay sensitivity.
• Blend uniformity.
• Pellet size and coating differences.
• Food-effect or administration-medium considerations.
• Dose recovery from soft food or liquid.
• Potential differences in gastrointestinal release.

These factors do not prevent generic entry, but they can increase development cost and delay approval.

What patent litigation affects BYLVAY?

The most important litigation risk is likely to arise when an ANDA filer submits a Paragraph IV certification against an Orange Book-listed patent. Under the Hatch-Waxman framework, timely patent litigation can trigger a 30-month stay of FDA approval, subject to statutory exceptions and court decisions.[4]

A commercial review should track:

Event	Relevance
Paragraph IV notice	Signals an intended generic challenge
Patent complaint	Starts the principal infringement dispute
30-month stay	Can delay FDA approval
Preliminary injunction request	May affect launch timing
Claim-construction ruling	Clarifies scope of formulation or method claims
Settlement agreement	May establish an authorized or future generic-entry date
FDA approval	Does not necessarily establish lawful commercial launch
At-risk launch	Creates potential damages and injunction exposure

No biosimilar interchangeability litigation is expected for BYLVAY because the product is not biologic.

What commercial opportunities exist for BYLVAY excipients?

The largest opportunities are lifecycle products that improve administration without changing odevixibat's mechanism.

Taste-masked pediatric pellets

A taste-masked product could target adherence and caregiver acceptance. Suitable technologies may include polymer-coated pellets or microencapsulated particles. The key development requirement is preserving the intended intestinal delivery and product stability.

Ready-to-use oral suspension

A liquid suspension could simplify administration for younger children. Its risks include chemical stability, sedimentation, microbial control, preservative tolerability, and dose uniformity after shaking. A suspension would need a strong clinical and commercial rationale because it could introduce new handling problems.

Feeding-tube-compatible formulation

A formulation validated for enteral tubes could serve patients with severe disease or feeding difficulties. Tube compatibility testing should assess clogging, adsorption, dose recovery, and interaction with tube materials.

Unit-dose pediatric packaging

Small, clearly labeled unit-dose packets could reduce caregiver dosing errors. Moisture protection is important for pellet products. Packaging patents may provide incremental protection, but packaging improvements are more likely to support market differentiation than block all generic competition.

Combination or co-packaged therapy

Patients with rare cholestatic diseases may receive multiple therapies. A co-packaged regimen could simplify treatment, although combination-product regulatory requirements and cross-product liability would increase complexity.

How does BYLVAY compare with competing cholestatic-pruritus therapies?

BYLVAY competes in a narrow rare-disease market rather than against conventional mass-market gastrointestinal drugs.

Product or class	Active ingredient	Formulation relevance	Competitive position
BYLVAY	Odevixibat	Capsules and oral pellets	Pediatric rare-disease positioning
LIVMARLI	Maralixibat	Oral solution	Liquid administration and pediatric use
Ursodeoxycholic acid	Ursodiol	Capsules, tablets, suspensions	Broad availability and lower-cost competition
Rifampicin and other off-label agents	Various	Conventional oral forms	Less targeted, variable evidence
Emerging IBAT inhibitors	Various	Product-specific	Potential class competition

LIVMARLI is the closest commercial comparator because it is also a pediatric-focused IBAT inhibitor marketed by Mirum. The principal formulation distinction is that LIVMARLI is supplied as an oral solution, while BYLVAY uses capsules and pellets. This creates a direct competition between solid multiparticulates and liquid dosing.

A liquid product may be easier for some infants to administer. Pellets may offer better stability, lower packaging volume, and lower risk of microbial contamination after opening. The commercial winner in a given patient population may depend on taste, dosing frequency, caregiver preference, payer coverage, and age.

What FDA regulatory issues apply to BYLVAY excipients?

Excipients in an approved product are subject to FDA review for identity, quality, safety, manufacturing control, and consistency. A new BYLVAY formulation would require regulatory support proportional to the change.

Key issues include:

• Pediatric safety of each excipient.
• Exposure to lactose and other allergen-related components.
• Acceptable daily intake for colorants and preservatives.
• Control of elemental impurities.
• Microbial limits.
• Stability under intended storage conditions.
• Dose uniformity across the full strength range.
• Compatibility with food, liquid, and administration devices.
• Demonstration that the formulation does not alter clinical performance.

A generic applicant may use different inactive ingredients, but the proposed excipients must be acceptable under FDA requirements and must not compromise pharmaceutical equivalence or bioequivalence.[5]

What geographic opportunities exist for BYLVAY excipient technology?

The best geographic opportunities are markets with:

• Pediatric rare-disease reimbursement.
• Established orphan-drug pathways.
• High use of enteral feeding.
• Limited access to compounding pharmacies.
• Strong demand for dose-flexible oral products.
• Regulatory acceptance of multiparticulate dosage forms.

The United States offers the largest near-term commercial value because of orphan-drug pricing and established specialty-pharmacy infrastructure. Europe may support differentiated pediatric formulations through national reimbursement and pediatric investigation requirements. Japan and other Asian markets may reward liquid or pellet formulations that fit local pediatric administration practices.

International patent strategies should separate compound protection from formulation protection. A formulation patent may have commercial value in one market where the reference product is widely reimbursed but limited value in another market with weak reimbursement or early compulsory substitution.

What generic launch scenarios exist for BYLVAY?

Three launch scenarios are commercially plausible:

1. Full substitution after compound and regulatory exclusivity expire.
2. Delayed entry after Paragraph IV litigation or settlement.
3. Partial entry using a carved-out label or alternative formulation.

The first generic entrant would likely have a cost advantage but face a limited patient pool and significant pharmacovigilance obligations. Specialty-generic economics are strongest when the product has high annual treatment cost, stable diagnosis rates, and limited manufacturing competition.

A capsule-only generic may initially avoid direct competition with pellet-specific administration features. If prescribers view pellets as essential for younger patients, the generic could capture older patients while leaving the pediatric segment protected by formulation differentiation.

Key Takeaways

• BYLVAY's excipient strategy supports low-dose, pediatric, oral administration.
• Oral pellets are commercially important because they address swallowing and caregiver-dosing constraints.
• The main formulation opportunities are taste masking, feeding-tube compatibility, improved dose recovery, and unit-dose packaging.
• Odevixibat is a small molecule, so generic competition would use the ANDA pathway rather than the biosimilar pathway.
• Formulation patents are strongest when they cover a complete multiparticulate system and performance characteristics, not a replaceable single excipient.
• The closest formulation competitor is LIVMARLI, which uses an oral solution rather than pellets and capsules.
• Orange Book patents, FDA exclusivity, Paragraph IV activity, and settlement agreements determine practical generic-entry timing.
• Commercial value depends on pediatric adherence, rare-disease reimbursement, manufacturing reproducibility, and caregiver administration.

FAQs

Can BYLVAY pellets be reformulated as a liquid?

Yes, a liquid version is technically possible, but it would require new stability, microbial-control, dose-uniformity, taste, and clinical-performance work. A suspension may create handling and sedimentation risks that do not apply to pellets.

Is lactose in BYLVAY a commercial formulation limitation?

Lactose can limit use in patients with specific intolerance or dietary concerns, but its commercial impact depends on the amount present, patient population, labeling, and availability of alternative formulations.

Could a generic BYLVAY use different excipients?

Yes. An ANDA applicant generally may use different inactive ingredients if the product meets pharmaceutical equivalence, bioequivalence, safety, quality, and labeling requirements. The applicant must also avoid infringement of valid formulation or manufacturing claims.

Does BYLVAY require a biosimilar approval?

No. Odevixibat is a chemically synthesized small molecule. A competing product would generally use the ANDA pathway for a generic drug, not the 351(k) biosimilar pathway.

Which excipient technology has the highest licensing potential?

Taste-masked, tube-compatible multiparticulate technology has the clearest licensing potential because it directly addresses pediatric administration, chronic adherence, and differentiation from conventional capsule products.

References

1. U.S. Food and Drug Administration. (2024). BYLVAY (odevixibat) prescribing information. FDA.
2. National Library of Medicine. (2024). DailyMed: BYLVAY-odevixibat capsule and oral pellets. DailyMed.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
4. U.S. Food and Drug Administration. (2023). Approved drug products and patent certification requirements under the Hatch-Waxman Amendments. FDA.
5. U.S. Food and Drug Administration. (2016). Inactive ingredient database. FDA.